Alexis R. Ogdie, MD, MSCE
Rheumatology
Accepting new patients
Sees patients age 18 and up
Penn Rheumatology Perelman
Schedule onlineCall 215-662-2454
Penn Medicine Provider

About me

  • Director, Center for Clinical Epidemiology and Biostatistics
  • Director, Penn Psoriatic Arthritis and Spondyloarthritis Program
  • Professor of Medicine (Rheumatology) at the Hospital of the University of Pennsylvania
  • Associate Professor of Epidemiology in Biostatistics and Epidemiology
  • Professor of Biostatistics and Epidemiology

Dr. Ogdie's research program is focused on inflammatory arthritis (IA) including psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and rheumatoid arthritis (RA). The mission of her research program is to improve outcomes in IA by accelerating diagnosis, increasing the focus on meaningful, patient-centered outcomes, and developing and advancing methods for precision medicine. Dr. Ogdie is an expert in the care of patients with IA, Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program and Director of the Penn Center for Clinical Epidemiology and Biostatistics.

Her areas of expertise include epidemiology and pharmacoepidemiology, biostatistical methods for observational studies (e.g., complex time to event modeling, prediction modeling), outcome measures (e.g., qualitative and quantitative/psychometric assessment), clinical trial design and more general qualitative methods (e.g., survey, focus group and interview studies). Her recent work has focused on a) pragmatic trial design and implementation including the recent launch of a first head-to-head pragmatic trial in PsA (EVOLUTION, NCT05669833); b) trials aimed at improving outcomes in PsA through holistic care including a trial to test Dietary Interventions in PsA (DIPSA, NCT04180904), and a new single arm trial to address whole patient care as a novel care paradigm in rheumatology (funded by a Rheumatology Research Foundation) and c) identifying risk factors for development of PsA among patients with psoriasis.

 

Education and training

  • Medical School: Georgetown University School of Medicine
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating

225 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
very good experience
November 2025
caring and knowledgeable
November 2025
always a good experience
October 2025
very pleasant and concerned and understanding of needs

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Ogdie is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF. Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial , Nat Med: 2025

Landzberg E, Ogdie A, Yarnell C, Harhay MO, Yehya N. Observational studies of early versus late salvage therapies in critical care exhibit intrinsic selection bias: two meta-analyses , Crit Care, 29: 2025,411

Armstrong AW, Mburu S, Gondo GC, Kornyeyeva E, Frade S, Ogdie A. Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study , Drugs Real World Outcomes: 2025

Mayer SE, Kluberg SA, Spence O, Oraichi D, Seifert H, Ali O, Yun H, Simon AL, Ko JS, Hugh C, Her M, Shattuck K, Jamal-Allial A, Djibo DA, Daniels K, Ma Q, McMahill-Walraven CN, Ogilvie RP, Palmsten K, Selvan M, Ziyadeh N, Ogdie A, George MD. Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA , RMD Open, 11: 2025,e005839

Wu A, Zhang A, Guo Y, Liu J, Yang DM, Chada LP, Ogdie A, Reddy SM, Gottlieb AB, Scher JU, Merola JF. Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis , JAMA Dermatol: 2025

Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L. Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies , RMD Open, 11: 2025,e005522

Rice AL, Gillespie S, Sai N, Reddy SM, Merola JF, Haberman RH, Ogdie A, Scher JU. Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics , J Psoriasis Psoriatic Arthritis: 2025

Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ; ICEBIO. Antimicrobial use and serious infections among psoriatic arthritis patients after initiating tumor necrosis factor inhibitors: a nationwide matched cohort study , J Rheumatol: 2025

Allenzara A, Bush K, Husni ME, Reddy SM, Scher JU, Craig E, Koplin J, Walsh JA, Ogdie A. Diverse Treatment Goals in Psoriatic Arthritis: Insights from participants in the PARC cohort , Arthritis Care Res (Hoboken): 2025

Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA. Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial , Trials, 26: 2025,96